Atlas Trials

First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

Clinical trial NCT06502743 · RECRUITING

Trial details

NCT number
NCT06502743
Sponsor
Yonsei University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Endometrial CancerRecurrent Endometrial CarcinomaEndometrial CarcinomaGynecologycal CancerEndometrial Neoplasms
Start date
2024-09-12
Primary completion
2027-12-01
Enrollment
92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.